Rapid Communication

Mutation of RET proto-oncogene in Hirschsprung’s disease and intestinal neuronal dysplasia

Jin-Fa Tou, Min-Ju Li, Tao Guan, Ji-Cheng Li, Xiong-Kai Zhu, Zhi-Gang Feng

Jin-Fa Tou, Min-Ju Li, Xiong-Kai Zhu, Zhi-Gang Feng, Department of Pediatric Surgery, the Children’s Hospital affiliated to the Medical College of Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Tao Guan, Ji-Cheng Li, Department of Lymphology, Department of Histology and Embryology, Zhejiang University Medical College, Hangzhou 310031, Zhejiang Province, China
Correspondence to: Xiong-Kai Zhu, Department of Pediatric Surgery, the Children’s Hospital affiliated to the Medical College of Zhejiang University, Hangzhou 310003, Zhejiang Province, China. zhuxk0914@yahoo.com.cn
Telephone: +86-571-87061007-60712
Received: 2005-06-20 Accepted: 2005-07-26

Abstract

AIM: To investigate the genetic relationship between Hirschsprung’s disease (HD) and intestinal neuronal dysplasia (IND) in Chinese population.

METHODS: Peripheral blood samples were obtained from 30 HD patients, 20 IND patients, 18 HD/IND combined patients and 20 normal individuals as control. Genomic DNA was extracted according to standard procedure. Exons 11, 13, 15, 17 of RET proto-oncogene were amplified by polymerase chain reaction (PCR). The mutations of RET proto-oncogene were analyzed by single strand conformational polymorphism (SSCP) and sequencing of the positive amplified products was performed.

RESULTS: Eight germline sequence variants were detected. In HD patients, 2 missense mutations in exon 11 at nucleotide 15165 G→A (G667S), 2 frameshift mutations in exon 13 at nucleotide 18974 (18974insG), 1 missense mutation in exon 13 at nucleotide 18919 A→G (K756E) and 1 silent mutation in exon 15 at nucleotide 20692 G→A (Q916Q) were detected. In HD/IND combined patients, 1 missense mutation in exon 11 at nucleotide 15165 G→A and 1 silent mutation in exon 13 at nucleotide 18888 T→G (L745L) were detected. No mutation was found in IND patients and controls.

CONCLUSION: Mutation of RET proto-oncogene is involved in the etiopathogenesis of HD. The frequency of RET proto-oncogene mutation is quite different between IND and HD in Chinese population. IND is a distinct clinical entity genetically different from HD.

© 2006 The WJG Press. All rights reserved.

Key words: RET proto-oncogene; Hirschsprung’s disease; Intestinal neuronal dysplasia

Tou JF, Li MJ, Guan T, Li JC, Zhu XK, Feng ZG. Mutation of RET proto-oncogene in Hirschsprung’s disease and intestinal neuronal dysplasia. World J Gastroenterol 2006; 12(7):1136-1139

http://www.wjgnet.com/1007-9327/12/1136.asp

INTRODUCTION

Hirschsprung’s disease (HD) is a frequent congenital malformation affecting one in 5000 births. It is characterized by the absence of ganglion cells in both the myenteric and submucosal plexuses along variable lengths of the hindgut leading to intestinal obstruction in neonates and severe constipation in infants and adults. The occurrence of most HD cases is sporadic, but 15-20% are in familial form[4]. Genetic analyses have illustrated several genes coding for components of signaling pathways including RET[5-9], GDNF[10-12], EDN3[13-15] and EDNRB[16-18] involved in occurrence of HD. Mutations of RET gene are responsible for a dominant form of HD and account for half of the familial cases and 0-50% of sporadic cases[16,17].

Intestinal neuronal dysplasia (IND), first described in 1971 by Meier-Ruge[19], is a malformation of the enteric nervous system and shows the clinical features similar to those of HD. The incidence of IND ranges 5-60% of all patients biopsied for suspected HD. The prominent histological features of IND are hyperganglionosis of submucosal and myenteric plexuses, giant ganglia containing more than seven nerve and ectopic ganglion cells[19,20]. IND often occurs proximal to the aganglionic segment in HD[19] and less frequently as an isolated condition. The etiology of IND is still unknown. Since IND and HD often occur in combination, the genesis gene of HD may also be involved in occurrence of IND. To clarify the genetic relationship between HD and IND in Chinese population, we performed genetic analysis of exons11, 13, 15, 17 of RET proto-oncogene in 30 HD patients, 20 IND patients, 18 HD/IND combined patients and 20 normal individuals as controls.

MATERIALS AND METHODS

Case selection and extraction of DNA
The diagnosis of all patients was confirmed histologically
by rectal biopsy and resected bowel specimens. The criteria for HD and IND were based on the guidelines put out by Holschneider et al[19] and Merier-Ruge et al[20]. Peripheral blood samples were obtained from all the patients and controls. All samples were anti-coagulated with sodium citrate. After white blood cells were isolated from each blood sample, genomic DNA was extracted according to standard procedure.

**Polymerase chain reaction**

Two hundred nanograms of genomic DNA was amplified in 50 µL reaction containing 10 mmol/L Tris-HCL (pH8.4), 50mmol/L KCL, 1.5 mmol/L MgCl2, 0.5 µmol/L each of two fragment specific primers, 100 µmol/L each of dATP, dGTP, dCTP and dTTP, 2 nits/mL of Tap DNA polymerae. The primers were synthesized by Shanghai Shenggong Biology Company. Exon11 (forward): 5'-ACACACCCCCACCCCCACAT-3'; (reverse):5' -AACCTGGAAGCCCATCAGG-3' (273bp). Exon13 (forward): 5'-GACCTGAGATGTCGATGGA-3'; (reverse):5'-AAGAGGGAGACACGGTGTA-3' (253bp). Exon15 (forward): 5'-GACTCGTGCTATTTTACCT-3'; (reverse):5'-TATCTTTCTAGGGCTCTCC-3' (234bp). Exon17(forward): 5'-CCCTACATGATGATACGG-3'; (reverse): 5'-TCACGTGCCTCTACCTCTC-3' (232bp). After denaturation at 94 ºC for 5 min, 30 cycles of PCR amplification were carried out at 94 ºC for 50 s, at 58 ºC - 62 ºC for 50 s, at 72 ºC for 50s, and a final extension at 72 ºC for 10 min.

**SSCP and sequence analysis**

The amplified fragments of RET proto-oncogene were analyzed for mutations by SSCP performed on a Mini Electrophoresis Unit (Bio-Rad Company, USA). Ten microliters of PCR products was mixed with 10 µL of loading buffer (90% formamide, 0.05% bromphenol blue dye and 0.05% xylene cyanol), heat denatured at 100 ºC for 5 min, immediately placed on ice for 3 min, and analyzed by 8% PAGE in 45 Mm-Tris-borate (pH8.0)/1Mm-EDTA (TBE) buffer under 13 v/cm at 10 ºC. The gels were stained with sliver, the bands were analyzed and photographed. Abnormal PCR products screened by SSCP were analyzed for mutations by SSCP performed on a Mini Sequencer. Abnormal bands were subested and sequenced using PE377 automated sequencer.

**RESULTS**

To determine the mutation of RET proto-oncogene and genomic relationship between HD and IND in Chinese population, we performed PCR-SSCP and sequence analysis of RET gene mutation in exons 11,13,15,17 in 30 HD patients, 20 IND patients , 18 HD/IND combined patients and 20 normal controls. Eight germline sequence variants were detected. In HD patients, 2 missense mutations in exon 11 at nucleotide 15165 G→A resulting in a G667S exchange in codon 667 and 2 frameshift mutations in exon 13 at nucleotide 18974 (18974insG), 1 missense mutation in exon13 at nucleotide 18919, and 1 silent mutation in exon 15 at nucleotide 20692 (Q916Q) were detected. In HD/IND combined patients, 1 missense mutation in exon 11 at nucleotide 15165 G→A and 1 silent mutation in exon 13 at nucleotide 18888 T→G (L745L) were found. All these mutations were heterozygous (Table 1). No mutation found in IND patients and controls.

**DISCUSSION**

The RET proto-oncogene is first detected by transfection of NIH 3T3 cells with human lymphoma DNA[21] which lies on chromosome band 10q11.2 and comprises 20 exons[22,23]. The product of the RET proto-oncogene is a RET protein, a member of the receptor tyrosine kinase superfamily consisting of a cadherin-like ligand-binding extracellular domain, a transmembrane domain, and an intracellular tyrosine kinase domain[24]. Genetic studies have demonstrated that the germline mutations of RET gene cause endocrine neoplasia and familial medullary thyroid carcinoma[25,26]. It was reported that the RET proto-oncogene is expressed in the early stage of embryogenesis and plays an important role in the differentiation of peripheral nervous system and the excretory system[27,28]. A number of studies showed that RET proto-oncogene is the causative gene for the development HD[29].

IND as a cause of severe chronic constipation remains controversial and shows the clinical features similar to those of HD. Both IND and HD demonstrate hyperplasia of mast cells (MC) and decreased synaptophysin (SY) activity in abnormal bowel[29,30]. Histological features of IND are hyperganglionosis of submucosal and myenteric plexuses , giant ganglia containing more than seven nerve and ectopic ganglion cells while HD is characterized by the absence of ganglion cells in myenteric and submucosal plexuses. Cajal hyperplasia has been found in IND as a cause of severe chronic constipation[30]. However, IND is not a neuromuscular junction disorder[31]. Wheatley et al[32] reported that...
IND is correlated with deficiency of substance P (SP) in myenteric axons. Although the occurrence of most INDs is sporadic, IND may have dominant autosomal inheritance[36,37]. Since IND shows the clinical features and certain immunohistochemistry activity similar to those of HD, mutations of RET proto-oncogene, a major causative gene for HD, may also cause IND.

In this study, 6 RET proto-oncogene mutations were detected in 30 HD patients including 1 silent mutation, 3 missense mutations and 2 frameshift mutations. The frequency of RET proto-oncogene mutation was 20% in Chinese HD patients, which is consistent with the reported frequency ranging 0-50%[38]. These mutations are heterozygous, suggesting that 50% of the RET proto-oncogene is likely to cause HD[39].

Two RET proto-oncogene mutations (1 silent mutation and 1 missense mutation) were detected in 18 HD/IND combined patients. However, we could not confirm that the mutation of RET proto-oncogene in HD/IND combined patients can cause IND or HD both. No RET proto-oncogene mutation was detected in 20 IND patients and 20 normal controls. Our data confirm that the frequency of RET gene mutation is quite different between IND and HD in Chinese population. Gath et al.[40] reported that 3 RET proto-oncogene mutations have been detected in 29 HD patients and no RET proto-oncogene mutation has been found in IND or IND/HD patients[10]. Barone et al.[39] performed linkage analysis in two IND pedigrees and demonstrated that IND is not linked to RET proto-oncogene mutation.

In conclusion, IND is a distinct clinical entity genetically different from HD. Further investigation is necessary to elucidate the pathogenesis of IND.

REFERENCES

1. Passarge E. The genetics of Hirschsprung’s disease. Evidence for heterogeneous etiology and a study of sixty-three families. N Engl J Med 1996; 327: 138-143
2. Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini I, Pasini B, Bocciardi R, Merone M, Kälärimäen H, Lehto M. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung’s disease. Nature 1994; 367: 377-378
3. Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L, Holder S, Nisho-Fékété C, Ponder BA, Munnich A. Mutations of the RET proto-oncogene in Hirschsprung’s disease. Nature 1994; 367: 378-380
4. Attié T, Pelet A, Eng C, Mulligan LM, Amiel J, Boutilier L, Beldjord C, Nisho-Fékété C, Munnich A. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet 1995; 4: 1381-1386
5. Shimotake T, Iwai N, Inoue K, Kimura T, Ichikawa D, Abe T, Inazawa J. Germline mutation of the RET proto-oncogene in children with total intestinal aganglionicosis. J Pediatr Surg 1997; 32: 498-500
6. Svensson PJ, Molander ML, Eng C, Anvret M, Nordenskjöld A. Low frequency of RET mutations in Hirschsprung disease in Sweden. Clin Genet 1998; 54: 39-44
7. Sancandi M, Ceccherini I, Costa M, Fava M, Chen B, Wu Y, Hofstra R, Laurie T, Griffiths M, Burge D, Tam PK. Incidence of RET mutations in patients with Hirschsprung’s disease. J Pediatr Surg 2000; 35: 139-142; discussion 142-143
8. Iwashita T, Kurokawa K, Qiao S, Muraikami H, Asai N, Kawai K, Hashimoto M, Watanabe T, Ichihara M, Takahashi M. Functional analysis of RET with Hirschsprung mutations affecting its kinase domain. Gastroenterology 2001; 121: 24-33
9. Fitz G, Cramer J, Ziegler A, Schierz M, Schreiber M, Kuhlisch E, Roesner D, Schackert HK. Association between c135G/A genotype and RET proto-oncogene germline mutations and phenotype of Hirschsprung’s disease. Lancet 2002; 359: 1200-1205
10. Gath R, Goessling A, Keller KM, Koletzko S, Coerdt W, Müntefering H, Wirth S, Hofstra RM, Mulligan L, Eng C, von Deimling A. Analysis of the RET, GDNF, EDN3, and EDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease. Gut 2001; 48: 671-675
11. Angrist M, Bolk S, Halushka M, Lapchak PA, Chakravarti A. Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient. Nat Genet 1996; 14: 341-344
12. Martucciello G, Thompson H, Mazzola C, Morando A, Bertagnon M, Negri F, Brizzolara L, Rocchetti L, Gambini C, Jasoni V. GDNF deficit in Hirschsprung’s disease. J Pediatr Surg 1998; 33: 99-102
13. Svensson PJ, Von Tell D, Molander ML, Anvret M, Norden-skjöld A. A heterozygous frameshift mutation in the endothelin-3 (EDN3) gene in isolated Hirschsprung’s disease. Pediatr Res 1995; 47: 714-717
14. Bidaud C, Salomon R, Van Camp G, Pelet A, Attié T, Eng C, Bonduelle M, Amiel J, Nisho-Fékété C, Willems PJ, Munnich A, Lyonnet S. Endothelin-3 gene mutations in isolated and syndromic Hirschsprung disease. Eur J Hum Genet 1997; 5: 247-251
15. Kusafuka T, Wang Y, Puri P. Mutation analysis of the RET, the endothelin-B receptor, and the endothelin-3 genes in sporadic cases of Hirschsprung’s disease. J Pediatr Surg 1997; 32: 501-504
16. Tanaka H, Moroi K, Iwai J, Takahashi H, Ohnuma N, Hori S, Takimoto M, Nishiyama M, Masaki T, Yanagisawa M, Sekiya S, Kimura S. Novel mutations of the endothelin B receptor gene in patients with Hirschsprung’s disease and their characterization. J Biol Chem 1998; 273: 11387-11383
17. Amiel J, Attié T, Jan D, Pelet A, Edery P, Bidaud C, Lacombe D, Tam P, Simeoni J, Flori E, Nisho-Fékété C, Munnich A, Lyonnet S. Heterozygous endothelin receptor B (EDNRB) mutations in isolated Hirschsprung disease. Hum Mol Genet 1996; 5: 355-357
18. Inoue M, Hosoda K, Imura K, Kamata S, Fukuwazawa M, Nakao K, Okada A. Mutational analysis of the endothelin-B receptor gene in Japanese Hirschsprung’s disease. J Pediatr Surg 1998; 33: 1206-1208
19. Holschneider AM, Meier-Ruge W, Ure BM. Hirschsprung disease and allied disorders—a review. Eur J Pediatr Surg 1994; 4: 260-266
20. Meier-Ruge W, Gambazzi F, Käufeler RE, Schmid P, Schmidt CP. The neuropsychological diagnosis of neuronal intestinal dysplasia (NIDB). Eur J Pediatr Surg 1994; 4: 267-273
21. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985; 42: 581-588
22. Ishizaka Y, Itoh F, Tahira T, Ikeda S, Sugimura T, Tucker J, Fertitta A, Cavrano AV, Nagao M. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 1989; 4: 1519-1521
23. Pasini B, Hofstra RM, Yin L, Bocciardi R, Santamarina G, Grootocholten PM, Ceccherini I, Patrone G, Priolo M, Buys CH. The physical map of the human RET proto-oncogene. Oncogene 1995; 11: 1737-1743
24. Takahashi M, Cooper GM. ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol 1987; 7: 1378-1385
25. Goodfellow PJ, Wells SA. RET gene and its implications for cancer. J Natl Cancer Inst 1995; 87: 1515-1523
26. Donis-Keller H. The RET proto-oncogene and cancer. J Intern Med 1995; 238: 319-325
27. Avantaggiato V, Dathan NA, Grieco M, Fabien N, Lazzaro D, Fusco A, Simeoni A, Santoro M. Developmental expression of the RET protooncogene. Cell Growth Diff 1994; 5: 305-311
28. Durbec PL, Larsson-Blomberg LB, Schuchardt A, Costantini F, Pachnis V. Common origin and developmental dependence
on c-ret of subsets of enteric and sympathetic neuroblasts. Development 1996; 122: 349-358
29 Demirbilek S, Ozardali HI, Aydm G. Mast-cells distribution and colonic mucin composition in Hirschsprung’s disease and intestinal neuronal dysplasia. Pediatr Surg Int 2001; 17: 136-139
30 Puri P. Variant Hirschsprung’s disease. J Pediatr Surg 1997; 32: 149-157
31 Jeng YM, Mao TL, Hsu WM, Huang SF, Hsu HC. Congenital interstitial cell of cajal hyperplasia with neuronal intestinal dysplasia. Am J Surg Pathol 2000; 24: 1568-1572
32 Newman CJ, Laurini RN, Lesbros Y, Reinberg O, Meyrat BJ. Interstitial cells of Cajal are normally distributed in both ganglionated and aganglionic bowel in Hirschsprung’s disease. Pediatr Surg Int 2003; 19: 662-668
33 Kobayashi H, Hirakawa H, Puri P. Is intestinal neuronal dysplasia a disorder of the neuromuscular junction? J Pediatr Surg 1996; 31: 575-579
34 Nogueira A, Campos M, Soares-Oliveira M, Estevão-Costa J, Silva P, Carneiro F, Carvalho JL. Histochemical and immunohistochemical study of the intrinsic innervation in colonic dysganglionosis. Pediatr Surg Int 2001; 17: 144-151
35 Wheatley JM, Hutson JM, Chow CW, Oliver M, Hurley MR. Slow-transit constipation in childhood. J Pediatr Surg 1999; 34: 829-32; discussion 832-833
36 Moore SW, Rode H, Millar AJ, Albertyn R, Cywes S. Familial aspects of Hirschsprung’s disease. Eur J Pediatr Surg 1991; 1: 97-101
37 Kobayashi H, Mahomed A, Puri P. Intestinal neuronal dysplasia in twins. J Pediatr Gastroenterol Nutr 1996; 22: 398-401
38 Sakai T, Wakizaka A, Nirasawa Y. Congenital central hypoventilation syndrome associated with Hirschsprung’s disease: mutation analysis of the RET and endothelin-signaling pathways. Eur J Pediatr Surg 2001; 11: 335-337
39 Barone V, Weber D, Luo Y, Brancolini V, Devoto M, Romeo G. Exclusion of linkage between RET and neuronal intestinal dysplasia type B. Am J Med Genet 1996; 62: 195-198